Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

An EU emergency health fund to limit the impact of future crises

Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU

- PMLiVE

BMS gains FDA approval for second Opdivo combo in kidney cancer

BMS' Opdivo/Yervoy regimen was its first combo to be approved for advanced renal cell carcinoma

- PMLiVE

AstraZeneca reduces initial COVID-19 vaccine deliveries to the EU

Deliveries in the first quarter have been cut by 60%

- PMLiVE

Pfizer/BioNTech reach vaccine supply agreement with COVAX

Up to 40 million doses will be supplied to the international vaccine-sharing facility

- PMLiVE

Mistrust in medical research: a patient perspective

The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...

Blue Latitude Health

- PMLiVE

Real-world evidence: breaking boundaries in rare disease

Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Blue Latitude Health

- PMLiVE

The heavy toll of COVID-19 on cancer patients

We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Blue Latitude Health

- PMLiVE

Unpacking rare diseases in the first edition of Delta magazine

Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization

Blue Latitude Health

Virtual HealthTech conference powered by Impetus Digital: A Customer Story

In this customer story, we summarize one of the pilot projects conducted using our new and award-winning platform: InSite Event™.

Impetus Digital

- PMLiVE

FDA priority review for Roche’s Esbriet in unclassifiable interstitial lung disease

Agency is due to make a decision for the approval by May 2021

- PMLiVE

Janet Woodcock named acting commissioner of the FDA

President Biden is set to formally nominate a commissioner soon

- PMLiVE

Lilly’s antibody bamlanivimab cuts COVID-19 risk by up to 80%

Bamlanivimab-treated care home residents and staff had a significant reduction in COVID-19 risk

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links